You are viewing a free preview of this lesson.
Subscribe to unlock all 21 lessons in this course and every other course on LearningBro.
Spec mapping: AQA 7138 Unit 3.3.3 — Strategy (refer to the official AQA specification document for exact wording). Lesson 6 framed why firms innovate (pressures) and what types of innovation exist; this lesson develops how firms organise innovation activity (R&D structures, kaizen, intrapreneurship, benchmarking, open innovation, corporate venturing, M&A) and how they protect the resulting value (patents, trademarks, copyright, design rights, trade secrets). The 6-mark Analyse prompt on this lesson asks the candidate to pick one IP-strategy decision — patent-protect or maintain as trade secret — and analyse its trade-off in a specific commercial context. Phase 2 depth here requires understanding that IP strategy is itself a strategic-finance decision: each protection mechanism has a cost, a duration, an enforcement profile and an opportunity-cost shape, and the right answer is contingent on the firm's competitive position and capital structure.
Connects to:
Firms have a portfolio of innovation methods available; the strategic question is which methods, in what combination, fit the firm's capability, capital and competitive position. The choice matters because methods have radically different cost structures, time horizons, control profiles and risk profiles.
Definition: Innovation methods are the organisational mechanisms through which firms generate, develop and commercialise new ideas. Intellectual property (IP) protection is the legal mechanism by which firms capture the commercial value of those innovations and prevent unauthorised use by competitors. Method choice and IP-strategy choice are mutually shaping decisions — a firm pursuing rapid open-innovation collaboration will adopt a different IP posture than a firm pursuing slow proprietary in-house R&D.
Three features make the innovation-method choice strategically loaded:
In-house R&D is the systematic, dedicated, internal approach to innovation generation. R&D divides into three stages — basic research (fundamental investigation without immediate commercial application), applied research (directed toward a specific commercial application), and development (translation into a marketable product or process).
| Stage | Mechanism | Worked example |
|---|---|---|
| Basic research | Fundamental scientific or engineering investigation without immediate commercial target | Bell Labs' decades of physics and information-theory research that underwrote the transistor, the laser, mobile telephony and information theory |
| Applied research | Investigation directed toward a defined commercial problem | Pharmaceutical drug-discovery programmes targeting specific disease mechanisms |
| Development | Translation of research findings into a viable product or process | Clinical-trial development, manufacturing-scale-up, regulatory submission |
R&D intensity (R&D spend as a percentage of revenue) varies dramatically by industry. The table below benchmarks the major sectors:
| Sector | Typical R&D intensity | Anchor example |
|---|---|---|
| Pharmaceuticals | 15-25 % of revenue | AstraZeneca spent ~£7.6bn on R&D in 2022 — over 20 % of revenue |
| Technology | 10-20 % of revenue | Alphabet (Google) spent ~$39.5bn on R&D in 2022 |
| Aerospace and defence | 5-10 % of revenue | Rolls-Royce, BAE Systems, Lockheed Martin all spend in this range |
| Automotive | 4-8 % of revenue | Volkswagen Group spent ~€18.9bn on R&D in 2022 |
| FMCG | 1-3 % of revenue | Unilever spent ~€1bn on R&D in 2022 |
| Retail | <1 % of revenue | Tesco's R&D spend is minimal as a proportion of revenue |
In-house R&D's principal advantages are control (the firm owns the IP outright) and capability accumulation (R&D activity builds enduring scientific and engineering competence). Its principal disadvantages are cost (R&D programmes are typically the largest discretionary spend line on a research-intensive firm's P&L) and risk (the failure rate of R&D programmes is structurally high — most pharmaceutical drug-discovery programmes fail to reach commercialisation).
Kaizen is the Japanese philosophy of continuous, small-scale, employee-driven improvement originated at Toyota as part of the Toyota Production System. The philosophical core is that many small improvements, applied consistently, produce cumulative gains larger than any single radical innovation could deliver — and that employees on the production line possess intimate process knowledge that senior managers lack.
| Feature | Detail |
|---|---|
| Origin | Toyota Production System, post-WWII Japan |
| Philosophy | Cumulative small improvements outperform episodic large ones; line workers possess essential process knowledge |
| Mechanism | Quality circles, suggestion schemes, andon (line-stop authority), visual management boards |
| Cultural prerequisite | Empowerment, no-blame culture, management commitment to implement employee suggestions |
At Toyota's Burnaston (Derbyshire) plant, workers are empowered to stop the production line via the andon system if they identify a defect. Teams meet regularly to discuss improvements, and the suggestion-scheme generates thousands of submitted improvements annually with material implementation rates. The cumulative cost-saving effect is structural rather than episodic.
Kaizen's principal advantages are low cost (improvements are small and inexpensive), employee engagement (people who design their own processes own them), and quality-and-waste reduction (cumulative defect-reduction and muda-elimination). Its principal disadvantages are limited individual impact (no single kaizen improvement is transformative), cultural-prerequisite fragility (kaizen requires a supportive organisational culture that hierarchical or low-trust firms struggle to create), and disruption-vulnerability (kaizen's sustaining-innovation strength does not protect against disruptive entrants).
Intrapreneurship is entrepreneurial activity within an existing organisation — employees given the autonomy, resources and senior support to develop new products, services or business models as if they were running their own startup, but within the resource and risk-absorption shelter of the parent firm. The Sony PlayStation (championed inside Sony by Ken Kutaragi against internal resistance from the music division), the 3M Post-it Note (developed by Spencer Silver and Art Fry within 3M's 15 %-time culture), Google Gmail (developed as Paul Buchheit's 20 %-time project), and Lockheed Martin's Skunk Works division are the canonical examples.
Intrapreneurship's principal advantages are creative-talent retention (the alternative is the talented employee leaving to start a competitor), internal-resource access (the intrapreneur uses the parent firm's capital, infrastructure and distribution), and risk-bounded experimentation (failed intrapreneurial projects are absorbed by the parent rather than destroying the individual). Its principal disadvantages are strategic-conflict risk (intrapreneurial projects may compete with the parent's core business — Sony's music division's resistance to PlayStation is the canonical example), cultural-fit requirements (intrapreneurship requires flat structures, tolerance of failure, and senior support that many large firms lack), and scaling difficulty (intrapreneurial culture is hard to maintain across organisations of 50,000+ employees).
Benchmarking is the structured comparison of the firm's performance, processes or practices against high-performing external reference points. Four sub-types are distinguished:
| Type | Reference point | Worked example |
|---|---|---|
| Internal benchmarking | Different departments, branches or divisions within the same firm | A supermarket chain comparing sales per square metre across its stores |
| Competitive benchmarking | Direct industry competitors | A UK airline comparing on-time performance against Ryanair and easyJet |
| Functional benchmarking | Best-in-class performers in a specific function, across any industry | A hospital benchmarking patient scheduling against Disney's theme-park queue management |
| Generic benchmarking | Broad business-process performers across unrelated industries | A manufacturer benchmarking logistics against Amazon's fulfilment operations |
Benchmarking's principal advantages are specific-improvement-target identification (benchmarking surfaces concrete gaps rather than vague aspirations), measurable-standard-setting (benchmarks provide objective targets), and low cost (the activity is analytically intensive but capital-light). Its principal disadvantages are imitation-not-innovation risk (benchmarking encourages copying rather than category-redefinition), backward-looking framing (benchmarks reflect current best-practice rather than future-required-practice), and transferability fragility (what works in one organisational context may fail in another).
Open innovation — the deliberate use of external knowledge sources to complement internal R&D — has emerged as a dominant innovation paradigm since the 2003 publication of Henry Chesbrough's Open Innovation. The mechanism spans formal partnerships (joint R&D agreements), university collaborations (sponsored research, doctoral programmes), supplier-driven innovation (co-development with key suppliers), customer-driven innovation (lead-user programmes), crowdsourcing (challenge prizes, hackathons) and corporate venturing (minority equity investments in startups).
Corporate venturing has become particularly significant: large firms invest in early-stage startups working in adjacent domains, both for the financial-return potential and for the strategic optionality on emerging technologies. Google Ventures, Intel Capital, Unilever Ventures and Microsoft's M12 are major corporate-venturing arms.
M&A — discussed in depth in the Mergers, Takeovers and Integration lesson — is the fastest way to acquire innovation capability. Pharmaceutical-industry M&A is overwhelmingly innovation-driven: large pharma firms acquire small biotech firms with promising drug-discovery pipelines. Technology-industry M&A is similarly innovation-driven: Google's acquisition of YouTube (2006), DeepMind (2014) and Looker (2019); Microsoft's acquisition of LinkedIn (2016), GitHub (2018) and Activision-Blizzard (2023); Meta's acquisition of Instagram (2012) and WhatsApp (2014).
M&A's principal advantage is speed (the firm acquires existing IP, talent and customer base in a single transaction). Its principal disadvantages are cost (acquisition premiums typically run 20-40 % above market price, and academic estimates suggest 50-70 % of large acquisitions destroy shareholder value) and integration risk (cultural and operational integration is hard, and key talent often departs post-acquisition).
flowchart TD
Strategy["Innovation strategy choice:<br/>build, buy or partner"] --> Build["Build:<br/>in-house R&D,<br/>kaizen,<br/>intrapreneurship,<br/>benchmarking"]
Strategy --> Partner["Partner:<br/>open innovation,<br/>joint R&D,<br/>corporate venturing"]
Strategy --> Buy["Buy:<br/>acquisition,<br/>licensing-in,<br/>IP purchase"]
Build --> IP1["IP outcome:<br/>proprietary patents,<br/>trade secrets"]
Partner --> IP2["IP outcome:<br/>shared/royalty IP,<br/>licensed rights"]
Buy --> IP3["IP outcome:<br/>acquired portfolio,<br/>licensed-in rights"]
IP1 --> Capture["Value capture:<br/>protection mechanism,<br/>enforcement strategy"]
IP2 --> Capture
IP3 --> Capture
Capture --> Outcome["Commercial outcome:<br/>differentiation,<br/>royalty revenue,<br/>competitive barrier"]
style Build fill:#15803d,color:#fff
style Partner fill:#1d4ed8,color:#fff
style Buy fill:#b91c1c,color:#fff
The diagram captures the build-buy-partner trichotomy. Each branch has a different cost profile, time horizon, control profile and IP-protection requirement. Strong innovation portfolios typically combine all three: in-house R&D for capability accumulation, partnerships for option-creation on uncertain technologies, and acquisitions for speed-to-capability when timing is critical.
Innovation creates commercial value only if the firm can capture it. Without IP protection, competitors can imitate freely and the innovator's competitive advantage evaporates. The five major IP-protection mechanisms each have distinct cost, duration, scope and enforcement profiles.
| Protection | What it covers | Duration (UK) | Cost profile | Disclosure required? |
|---|---|---|---|---|
| Patent | New, inventive, industrially applicable inventions — products, processes, technical solutions | Up to 20 years from filing | High — application £4-10k+, plus renewal fees; enforcement litigation £100k-£1m+ | Yes — full technical disclosure published |
| Copyright | Original literary, artistic, musical, dramatic works; software code | Life of creator + 70 years | Automatic on creation — zero registration cost; enforcement cost variable | No — automatic, no disclosure |
| Trademark | Brand names, logos, slogans, distinctive signs | Renewable indefinitely (10-year cycles) | Low — registration £170+ in UK; renewal modest | No — only registration of the mark |
| Design right | Visual appearance — shape, pattern, configuration | Up to 25 years (registered); 15 years (unregistered) | Low to moderate — registered design £50+ in UK | Yes — registered designs published |
| Trade secret | Confidential business information providing competitive advantage | Indefinite — as long as secrecy maintained | Zero registration; substantial internal protection cost (security, NDAs, employment-contract terms) | No — secrecy is the whole protection |
For inventions that could be either patented or kept as trade secrets, the strategic choice is consequential. The Coca-Cola formula has been a trade secret for over 130 years — substantially longer than any patent would have provided. Conversely, Dyson's cyclone vacuum technology was patented and successfully defended in court (Hoover's "triple vortex" infringement, ~£4m damages, 2001) — patent disclosure was strategically acceptable because Dyson's continued innovation cadence kept it ahead of post-expiry generic competitors.
The decision turns on six factors:
| Factor | Patent | Trade secret |
|---|---|---|
| Reverse-engineerability | If competitors can reverse-engineer the invention from the product, patent is essential | If reverse-engineering is impossible (formula, process), trade secret is viable |
| Duration of competitive advantage | 20-year fixed term | Indefinite if secrecy maintained |
| Geographic scope | Must file separately in each jurisdiction (expensive globally) | Inherently global (secrecy works everywhere) |
| Enforcement | Public, structured, costly | Private, requires demonstrable misappropriation |
| Disclosure cost | Full technical disclosure published — competitors learn the invention | No disclosure — competitors learn nothing |
| Strategic-signalling value | Patent portfolio is visible to investors, talent and competitors | Invisible — provides no signalling value |
Subscribe to continue reading
Get full access to this lesson and all 21 lessons in this course.